HRT Financial LP filed a Schedule 13G with the SEC on November 19, 2026, disclosing a 10.9% beneficial ownership position in bioAffinity Technologies, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: HRT Financial LP reported 127,132 shares of common stock beneficially owned as of September 30, 2026.
  • Ownership percentage: The 127,132 shares represent 10.9% of the class, according to the filing.
  • Direct holdings plus warrants: The aggregate includes 126,146 shares held directly and 986 shares issuable upon the exercise of certain warrants held by HRT Financial LP.
  • Sole voting and dispositive power: HRT Financial LP reported sole voting power and sole dispositive power over all 127,132 shares, with no shared voting or dispositive power.
  • Share count basis: The 10.9% figure is based on 1,166,625 shares outstanding as of September 30, 2026, plus the 986 warrant shares, for a denominator of 1,167,611 shares.
  • Filer classification: HRT Financial LP is identified as a broker-dealer (type "BD") and is organized as a Delaware limited partnership, operating care of Hudson River Trading LLC in New York.

HRT Financial LP Crosses 10% Threshold in bioAffinity Technologies Common Stock

HRT Financial LP, a Delaware limited partnership operating care of Hudson River Trading LLC at 3 World Trade Center, 175 Greenwich Street, New York, filed a Schedule 13G disclosing its position in bioAffinity Technologies, Inc. (NASDAQ:BIAF), whose principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217. The filing covers ownership as of September 30, 2026, and was signed by Adam Nunes, CEO, on November 19, 2026.

According to the filing, the aggregate beneficial ownership of 127,132 shares consists of 126,146 shares of common stock held directly and 986 shares of common stock issuable upon the exercise of certain warrants. The filing states that HRT Financial LP holds sole voting power and sole dispositive power over the entire 127,132-share position, with zero shared voting power and zero shared dispositive power reported.

The percentage of class, 10.9%, was calculated using a denominator of 1,167,611 shares, which the filing describes as 1,166,625 shares of common stock outstanding as of September 30, 2026, as reported by bioAffinity Technologies in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 6, 2026, plus the 986 warrant shares held by HRT Financial LP. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

HRT Financial LP disclosed a 10.9% beneficial ownership stake in bioAffinity Technologies, Inc. common stock as of September 30, 2026, comprising 126,146 directly held shares and 986 warrant-linked shares, with sole voting and dispositive power over the full position.